Healthcare >> Analyst Interviews >> October 21, 2002

Cardiology & Neuromodulation: Mark Landy – Leerink Swann & Co

MARK LANDY is a Vice President and Senior Research Analyst at Leerink Swann & Company. Prior to joining the firm he was associated with Investor AB, Merlin BioMed Group, and New Era Capital. Mr. Landy earned a DDS from the University of the Witwatersrand, South Africa, and a BBA from The Wharton School, University of Pennsylvania. Mr. Landy is a member of the South African Medical and Dental Council, the South African Society of Surgeons, the British Medical Council and the British Dental Association. JAN WALD joined A.G. Edwards in June 2000 and focuses his research efforts in the medical technology industry. Dr. Wald is an active publisher of industry and company-specific research reports focused in the areas of cardiology and neurology. He has previous work experience in the medical technology industry, working at Guidant Corp. and Honeywell, Inc. At Guidant, Dr. Wald managed clinical programs as well as the development of the algorithms and software for two implantable defibrillators. At Honeywell he managed image processing algorithm and robotics programs. Prior to joining A.G. Edwards, Dr. Wald was a Senior Vice President and Senior Analyst in medical technology at George K. Baum & Co. He has a PhD from Brandeis University and an MBA from University of St. Thomas. Dr. Wald also holds a patent on atrial fibrillation detection. Profile
TWST: Could you define your coverage universe for us?

Mr. Landy: Currently we cover companies that participate in the

cardiovascular and neurovascular arena. In the cardiovascular

space we